R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma

Antonio Omuro, Denise D. Correa, Lisa M. DeAngelis, Craig Moskowitz, Matthew J. Matasar, Thomas J. Kaley, Igor T. Gavrilovic, Craig Nolan, Elena Pentsova, Christian C. Grommes, Katherine S. Panageas, Raymond E. Baser, Geraldine Faivre, Lauren E. Abrey, Craig S. Sauter

Research output: Contribution to journalArticle

119 Citations (Scopus)

Abstract

High-dose methotrexate-based chemotherapy is the mainstay of treatment of primary central nervous system lymphoma (PCNSL), but relapses remain frequent. High-dose chemotherapy (HDC) with autologous stem-cell transplant (ASCT) may provide an alternative to address chemoresistance and overcomethe blood-brain barrier. In this single-center phase-2 study, newly diagnosed PCNSL patients received 5 to 7 cycles of chemotherapy with rituximab, methotrexate (3.5 g/m2), procarbazine, and vincristine (R-MPV). Those with a complete or partial response proceeded with consolidation HDC with thiotepa, cyclophosphamide, and busulfan, followed by ASCT and no radiotherapy. Primary end point was 1-year progression-free survival (PFS), N = 32. Median age was 57, and median Karnofsky performance status 80. Following R-MPV, objective response rate was 97%, and 26 (81%) patients proceeded with HDC-ASCT. Among all patients, median PFS and overall survival (OS) were not reached (median follow-up: 45 months). Two-year PFS was 79% (95% confidence interval [CI], 58-90), with no events observed beyond 2 years. Two-year OS was 81% (95% CI, 63-91). In transplanted patients, 2-year PFS and OS were 81%. There were 3 treatment-related deaths. Prospective neuropsychological evaluations suggested relatively stable cognitive functions posttransplant. In conclusion, this treatment was associated with excellent disease control and survival, an acceptable toxicity profile, and no evidence of neurotoxicity thus far.

Original languageEnglish (US)
Pages (from-to)1403-1410
Number of pages8
JournalBlood
Volume125
Issue number9
DOIs
StatePublished - Feb 26 2015
Externally publishedYes

Fingerprint

Transplants
Chemotherapy
Stem cells
Lymphoma
Stem Cells
Disease-Free Survival
Drug Therapy
Survival
Neurology
Methotrexate
Central Nervous System
Confidence Intervals
Thiotepa
Disease control
Procarbazine
Karnofsky Performance Status
Busulfan
Radiotherapy
Vincristine
Blood-Brain Barrier

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. / Omuro, Antonio; Correa, Denise D.; DeAngelis, Lisa M.; Moskowitz, Craig; Matasar, Matthew J.; Kaley, Thomas J.; Gavrilovic, Igor T.; Nolan, Craig; Pentsova, Elena; Grommes, Christian C.; Panageas, Katherine S.; Baser, Raymond E.; Faivre, Geraldine; Abrey, Lauren E.; Sauter, Craig S.

In: Blood, Vol. 125, No. 9, 26.02.2015, p. 1403-1410.

Research output: Contribution to journalArticle

Omuro, A, Correa, DD, DeAngelis, LM, Moskowitz, C, Matasar, MJ, Kaley, TJ, Gavrilovic, IT, Nolan, C, Pentsova, E, Grommes, CC, Panageas, KS, Baser, RE, Faivre, G, Abrey, LE & Sauter, CS 2015, 'R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma', Blood, vol. 125, no. 9, pp. 1403-1410. https://doi.org/10.1182/blood-2014-10-604561
Omuro, Antonio ; Correa, Denise D. ; DeAngelis, Lisa M. ; Moskowitz, Craig ; Matasar, Matthew J. ; Kaley, Thomas J. ; Gavrilovic, Igor T. ; Nolan, Craig ; Pentsova, Elena ; Grommes, Christian C. ; Panageas, Katherine S. ; Baser, Raymond E. ; Faivre, Geraldine ; Abrey, Lauren E. ; Sauter, Craig S. / R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. In: Blood. 2015 ; Vol. 125, No. 9. pp. 1403-1410.
@article{ec6131198a7e4910b14c505512a891df,
title = "R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma",
abstract = "High-dose methotrexate-based chemotherapy is the mainstay of treatment of primary central nervous system lymphoma (PCNSL), but relapses remain frequent. High-dose chemotherapy (HDC) with autologous stem-cell transplant (ASCT) may provide an alternative to address chemoresistance and overcomethe blood-brain barrier. In this single-center phase-2 study, newly diagnosed PCNSL patients received 5 to 7 cycles of chemotherapy with rituximab, methotrexate (3.5 g/m2), procarbazine, and vincristine (R-MPV). Those with a complete or partial response proceeded with consolidation HDC with thiotepa, cyclophosphamide, and busulfan, followed by ASCT and no radiotherapy. Primary end point was 1-year progression-free survival (PFS), N = 32. Median age was 57, and median Karnofsky performance status 80. Following R-MPV, objective response rate was 97{\%}, and 26 (81{\%}) patients proceeded with HDC-ASCT. Among all patients, median PFS and overall survival (OS) were not reached (median follow-up: 45 months). Two-year PFS was 79{\%} (95{\%} confidence interval [CI], 58-90), with no events observed beyond 2 years. Two-year OS was 81{\%} (95{\%} CI, 63-91). In transplanted patients, 2-year PFS and OS were 81{\%}. There were 3 treatment-related deaths. Prospective neuropsychological evaluations suggested relatively stable cognitive functions posttransplant. In conclusion, this treatment was associated with excellent disease control and survival, an acceptable toxicity profile, and no evidence of neurotoxicity thus far.",
author = "Antonio Omuro and Correa, {Denise D.} and DeAngelis, {Lisa M.} and Craig Moskowitz and Matasar, {Matthew J.} and Kaley, {Thomas J.} and Gavrilovic, {Igor T.} and Craig Nolan and Elena Pentsova and Grommes, {Christian C.} and Panageas, {Katherine S.} and Baser, {Raymond E.} and Geraldine Faivre and Abrey, {Lauren E.} and Sauter, {Craig S.}",
year = "2015",
month = "2",
day = "26",
doi = "10.1182/blood-2014-10-604561",
language = "English (US)",
volume = "125",
pages = "1403--1410",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "9",

}

TY - JOUR

T1 - R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma

AU - Omuro, Antonio

AU - Correa, Denise D.

AU - DeAngelis, Lisa M.

AU - Moskowitz, Craig

AU - Matasar, Matthew J.

AU - Kaley, Thomas J.

AU - Gavrilovic, Igor T.

AU - Nolan, Craig

AU - Pentsova, Elena

AU - Grommes, Christian C.

AU - Panageas, Katherine S.

AU - Baser, Raymond E.

AU - Faivre, Geraldine

AU - Abrey, Lauren E.

AU - Sauter, Craig S.

PY - 2015/2/26

Y1 - 2015/2/26

N2 - High-dose methotrexate-based chemotherapy is the mainstay of treatment of primary central nervous system lymphoma (PCNSL), but relapses remain frequent. High-dose chemotherapy (HDC) with autologous stem-cell transplant (ASCT) may provide an alternative to address chemoresistance and overcomethe blood-brain barrier. In this single-center phase-2 study, newly diagnosed PCNSL patients received 5 to 7 cycles of chemotherapy with rituximab, methotrexate (3.5 g/m2), procarbazine, and vincristine (R-MPV). Those with a complete or partial response proceeded with consolidation HDC with thiotepa, cyclophosphamide, and busulfan, followed by ASCT and no radiotherapy. Primary end point was 1-year progression-free survival (PFS), N = 32. Median age was 57, and median Karnofsky performance status 80. Following R-MPV, objective response rate was 97%, and 26 (81%) patients proceeded with HDC-ASCT. Among all patients, median PFS and overall survival (OS) were not reached (median follow-up: 45 months). Two-year PFS was 79% (95% confidence interval [CI], 58-90), with no events observed beyond 2 years. Two-year OS was 81% (95% CI, 63-91). In transplanted patients, 2-year PFS and OS were 81%. There were 3 treatment-related deaths. Prospective neuropsychological evaluations suggested relatively stable cognitive functions posttransplant. In conclusion, this treatment was associated with excellent disease control and survival, an acceptable toxicity profile, and no evidence of neurotoxicity thus far.

AB - High-dose methotrexate-based chemotherapy is the mainstay of treatment of primary central nervous system lymphoma (PCNSL), but relapses remain frequent. High-dose chemotherapy (HDC) with autologous stem-cell transplant (ASCT) may provide an alternative to address chemoresistance and overcomethe blood-brain barrier. In this single-center phase-2 study, newly diagnosed PCNSL patients received 5 to 7 cycles of chemotherapy with rituximab, methotrexate (3.5 g/m2), procarbazine, and vincristine (R-MPV). Those with a complete or partial response proceeded with consolidation HDC with thiotepa, cyclophosphamide, and busulfan, followed by ASCT and no radiotherapy. Primary end point was 1-year progression-free survival (PFS), N = 32. Median age was 57, and median Karnofsky performance status 80. Following R-MPV, objective response rate was 97%, and 26 (81%) patients proceeded with HDC-ASCT. Among all patients, median PFS and overall survival (OS) were not reached (median follow-up: 45 months). Two-year PFS was 79% (95% confidence interval [CI], 58-90), with no events observed beyond 2 years. Two-year OS was 81% (95% CI, 63-91). In transplanted patients, 2-year PFS and OS were 81%. There were 3 treatment-related deaths. Prospective neuropsychological evaluations suggested relatively stable cognitive functions posttransplant. In conclusion, this treatment was associated with excellent disease control and survival, an acceptable toxicity profile, and no evidence of neurotoxicity thus far.

UR - http://www.scopus.com/inward/record.url?scp=84923913760&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923913760&partnerID=8YFLogxK

U2 - 10.1182/blood-2014-10-604561

DO - 10.1182/blood-2014-10-604561

M3 - Article

C2 - 25568347

AN - SCOPUS:84923913760

VL - 125

SP - 1403

EP - 1410

JO - Blood

JF - Blood

SN - 0006-4971

IS - 9

ER -